Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.

Login to start reading, or Join ESMO - All articles are Open Access after 6 months.

Filter by:

58 results

Anticancer Agents;  Cervical Cancer;  Immunotherapy

Final KEYNOTE-826 Survival Findings Support Pembrolizumab Use

From ASCO 2023 Annual Meeting:
Survival outcomes for persistent, recurrent or metastatic cervical cancer are significantly improved with the use of pembrolizumab alongside chemotherapy, regardless of bevacizumab therapy

Anticancer Agents;  Immunotherapy;  Non-Small Cell Lung Cancer;  Surgical Oncology

Perioperative Pembrolizumab Strategy Improves Resectable NSCLC Outcomes

From ASCO 2023 Annual Meeting:
Interim KEYNOTE-671 findings demonstrate an event-free survival benefit with use of pembrolizumab before and after surgery for patients undergoing treatment for early-stage, non-small-cell lung cancer  

Anticancer Agents;  Breast Cancer;  Immunotherapy;  Therapy;  Translational Research

IMpassion031: Atezolizumab Fails To Significantly Improve Early-Stage TNBC Survival

From ESMO Breast Cancer 2023:
Patients given neoadjuvant atezolizumab alongside chemotherapy for stage II–III triple-negative breast cancer are more likely to achieve pathological complete response but do not have better survival 

Breast Cancer;  Clinical Research;  Head and Neck Cancers;  Personalised/Precision Medicine

Mutant-Specific PI3Kα Inhibitor Overcomes Toxicity Limitations of Drug Class

From the 2023 AACR Annual Meeting:
RLY-2608, a mutant-selective PI3Kα inhibitor, may offer patients with PIK3CA-mutant solid tumours a chance of treatment without experiencing the toxic effects of non-selective PI3Kα inhibition  

Central Nervous System Malignancies;  Gynaecological Malignancies;  Hepatobiliary Cancers;  Pancreatic Cancer;  Personalised/Precision Medicine

FIGHT-207 Demonstrates Pemigatinib Activity Outside of Cholangiocarcinoma

From the 2023 AACR Annual Meeting:
Patients with gliomas, gynaecological tumours and pancreatic cancer could benefit from treatment with pemigatinib if they harbour an FGFR mutation

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.